Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy
- 27 April 2005
- journal article
- clinical trial
- Published by Wiley in Pediatric Pulmonology
- Vol. 40 (1), 15-21
- https://doi.org/10.1002/ppul.20237
Abstract
It is not known whether cytokine levels in sputum may be used as outocome measures after parenteral antibiotic therapy in cystic fibrosis (CF) patients. Here, we assessed the effects of antibiotic therapy on cytokine levels in sputum and serum obtained from young CF patients. Thirty‐two CF patients (14 females; mean age, 18.6 years; range, 11.4–35.7 years), consecutively admitted at the CF Center of Milan for parenteral antibiotic therapy during pulmonary exacerbation, were enrolled in the study. Before and after 21 days (range, 5–41) of intravenous antibiotic treatment, all patients underwent routine laboratory determinations (including white blood cell (WBC) count and C‐reactive protein (CRP)), a chest X‐ray, pulmonary function tests (forced expiratory volume in 1 sec (FEV1) and forced vital capacity (FVC) as % predicted), and sputum cultures. Interleukin (IL)‐6, IL‐8, IL‐10, and tumor necrosis factor (TNF)‐α levels in serum and sputum samples were determined by means of immunometric assays. After therapy, FEV1 and FVC significantly improved (median increase of 7.5% and 8.5% predicted, respectively), while CRP and WBC count were signifcantly decreased (median values from 14 to 5.5 mg/dl and from 8,350 to 7,400 n/mm3, respectively). While levels of IL‐6 and IL‐10 in sputum were generally undetectable, IL‐8 and TNF‐α were always measurable, and IL‐8 levels significantly decreased after antibiotic treatment (median values from 7,165 to 5,415 pg/ml). Following antibiotic therapy, IL‐8 and TNF‐α levels in sputum were inversely related with both FEV1 and FVC. In conclusion, TNF‐α and IL‐8 levels in sputum of young CF patients with pulmonary exacerbation were always detectable and may be useful, noninvasive outcome measures to assess response to therapy in CF patients.Keywords
This publication has 39 references indexed in Scilit:
- A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalitiesThe Journal of Pediatrics, 2001
- A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung DiseaseHuman Gene Therapy, 2001
- TNF-A and IL-8 in Consecutive Sputum Samples from Cystic Fibrosis Patients During Antibiotic TreatmentScandinavian Journal of Infectious Diseases, 2000
- Nasal and Bronchoalveolar Lavage Fluid Cytokines in Early Cystic FibrosisThe Journal of Infectious Diseases, 1997
- Effect of High-Dose Ibuprofen in Patients with Cystic FibrosisNew England Journal of Medicine, 1995
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisNew England Journal of Medicine, 1994
- Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4The Lancet, 1993
- Cytokines in sputum and serum from patients with cystic fibrosis and chronic pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs.Pediatric Pulmonology, 1993
- Sputum cysteinyl‐leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosisPediatric Pulmonology, 1992
- Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosisThe Journal of Pediatrics, 1988